Interim Results

RNS Number : 0187L
Inspecs Group PLC
08 September 2021
 

8 September 2021

INSPECS Group plc

("INSPECS", "the Company" or "the Group")

 

Interim Results

 

INSPECS Group plc, a global eyewear and lens design house and manufacturer, presents its interim results for the six months ended 30 June 2021. 

Financial highlights:

· Revenue increased to $125.7m (H1 2020: $16.7m)

· Gross profit margin 44.9% (H1 2020: 44.5%)

· Underlying gross profit margin* 49.8% (H1 2020: 44.5%) 

· Underlying EBITDA* increased to $17.7m (H1 2020: $0.7m)

· Underlying basic Earnings Per Share (EPS) of $0.17 (H1 2020: $0.01), with underlying diluted EPS of $0.16 (H1 2020: $0.01)

· Reported loss before tax of $2.6m (H1 2020: $8.3m) 

· Reported loss after tax of $3.2m (H1 2020: $7.5m)

· Reported basic EPS of $(0.03) (H1 2020: $(0.12)), with diluted EPS of $(0.03) (H1 2020: $(0.12))

· Strong balance sheet with cash at 30 June 2021 of $37.7m (30 June 2020: $28.6m)

· Cash flow from operating activities $15.4m (H1 2020: $(2.5)m)

*Underlying gross profit margin for H1 2021 excludes $6.1m purchase price allocation adjustment relating to inventory valuation following the acquisition of Eschenbach on 16 December 2020. Underlying EBITDA excludes this purchase price allocation adjustment and share based payment expense for the period. See 'Underlying EBITDA' table below for reconciliation to operating profit as shown below.

 

Operational highlights:

· Despite the restrictions of Covid-19, operations have remained fully functional and the business is currently transitioning from a work at home basis to a flexible office/home-working environment where applicable.

· Construction work on our Vietnam plant has been completed, despite Covid-19 related restrictions, production is at good levels.

· Further land acquired in Vietnam allows an additional expansion of manufacturing capacity.

· New B2B digital platform increases revenues.

· Eschenbach integration continues across the Group.

· Launch of new in-house designed and manufactured sustainable frames "Botaniq TM" continues to prove successful.

· Development of antiviral and antibacterial products for healthcare markets.

· Norville appointed UK sales distributor for "LEICA Lenses".

· Construction of new Norville production facility underway, completion expected Q4 2021.

· ESG teams working to move Group's offices to carbon neutral.

 

Robin Totterman, CEO of INSPECS, said:

"I am pleased to report our underlying EBITDA increased from $0.7m for the 6 months to 30 June 2020 to $17.7m for the 6 months to 30 June 2021. These are good results for the Group that demonstrate its trajectory following the acquisition of Eschenbach on the 16 December 2020.

 

"These results reflect the hard work that our employees have put in to ensure that the Group can operate despite Covid-19 restrictions. My thanks for the flexibility our teams have displayed across the globe. Our factories have managed to carry on producing in what has been an extraordinarily difficult time and all our factory workers in Vietnam have been vaccinated to enable them to carry on production. Our plant in China has continued to operate despite Covid-19 difficulties throughout the period. Our teams across the globe continue to drive new innovation, explore opportunities and expand into new markets through integration, organic growth and acquisitions.

"We have strong order books and notwithstanding the potential future disruption from Covid-19 our full year expections remain unchanged. We look forward to providing a further update with our Q3 trading update at the end of October."

 

For further information please contact:

 

INSPECS Group plc

Robin Totterman (CEO)

Chris Kay (CFO)

 

via FTI Consulting

Tel: +44 (0) 20 3727 1000

Peel Hunt (Nominated Adviser and Broker)

Adrian Trimmings

Andrew Clark

 

 

Tel: +44 (0) 20 7418 8900

FTI Consulting (Financial PR)

Alex Beagley

Fern Duncan

Alice Newlyn

 

Tel: +44 (0) 20 3727 1000

INSPECS@fticonsulting.com

 

About INSPECS Group plc

 

INSPECS is a Bath-based designer, manufacturer and distributor of eyewear frames and optically advanced spectacle lenses. The Group produces a broad range of frames and lenses, covering optical, sunglasses and safety, which are either "Branded" (either under licence or under the Group's own proprietary brands), or "OEM" (including private label on behalf of retail customers and un-branded).

 

In December 2020, INSPECS acquired Eschenbach, a leading, global, eyewear supplier headquartered in Nuremberg, Germany, which includes the American company Tura. The acquisition extended the Group's presence internationally in key global markets. This followed the acquisition of lens maker Norville in July 2020, whereby INSPECS combined two heritage brands in British optical, Savile Row frame maker, and Norville lens maker, further enhancing its vertically integrated business model. As one of only a few companies that can offer this one-stop-shop solution to global retail chains, INSPECS is well positioned to continue to take market share in the globally expanding eyewear market.

 

INSPECS customers include global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 70,000 points of sale.

 

INSPECS has operations across the globe: with offices in the UK, Portugal, Scandinavia, the US and China (Hong Kong, Macau and Shenzhen), and manufacturing facilities in Vietnam, China, the UK and Italy. With the acquisition of Eschenbach, the Group's international reach further extends across Europe and the American markets.

 

The Group's growth strategy going forward is to: (i) continue to grow organically; (ii) undertake further acquisitions (and drive value through leveraging the Group's internal capabilities); and (iii) extend the Group's manufacturing capacity.

 

More information is available at www.INSPECS.com .

 

CHIEF EXECUTIVE REVIEW

I am pleased to present our first full 6-month interim results following our acquisition of Eschenbach on 16 December 2020. The Group has performed well in the first 6-months with sales of $125.7m. The Group made an underlying EBITDA of $17.7m.

The Group continues to deliver despite Covid-19 restrictions around the globe. As we move towards the end of our financial year, I remain cautious but believe that we have developed over the last 12-months the ability to quickly change both our working and trading patterns to be able to continue to achieve solid results despite the challenging environment.

In Vietnam, unlike many other factories, our team has adapted to the complex Covid-19 restrictions. We quickly built new dormitories and shower facilities allowing our workforce to remain on-site and continue production.

We have sourced a new factory for Norville, and this move to a state-of-the-art production facility should be completed by the end of Q4. Norville has been appointed as the sole UK lens distributor for "LEICA Lenses".

Eschenbach has traded ahead of expectations, and it is great to see the collaboration of the Eschenbach teams with the other Group members around the globe taking shape. This continues to drive new and innovative ideas to further grow the Group.

We continue to work on further acquisitions with our advisors, as the enlarged Group now has many additional opportunities available to it.

Our new in-house innovation development team, 'Skunk Works', has been busy, and I hope to announce further advanced innovation in the near future.

Despite Covid-19, the Group continues to trade well post 30 June 2021. The global eyewear market has proved to be resilient over the last 18 months. However, current trading patterns can be quickly influenced by governments  around the world responding to the Covid-19 pandemic, which could see some of our markets affected.

Our order books continue to grow, and I am excited about new opportunities across the Group. Assuming current conditions prevaiI, I expect that we will continue to build on our results for the first 6 months of the year.

During the period we have worked hard across the Group on unifying ESG policies, with teams in place around the globe, targeting new environmentally friendly products for the market and a constant reduction in our waste, energy usage and carbon emissions.

Finally, I would like to thank all of our staff and advisors who have worked tirelessly in challenging circumstances to produce these results and have the passion and skills to continue the Group's growth.

Robin Totterman

8 September 2021

 

FINANCIAL REVIEW

 

The Group has produced a good financial performance despite Covid-19 restriction for the first 6-month period of 2021. The results include the first full six month period of Eschenbach GmbH.

 

Revenue

 

Revenue increased to $125.7m from $16.7m in H1 FY20 driven by the continuing integration of Eschenbach and volume growth across the diversity of markets that we now operate in.

 

Underlying Gross Margin

 

The Group's underlying gross margin increased from 44.5% to 49.8%.

 

Underlying EBITDA

 

The Group underlying EBITDA increased from $0.7m in H1 2020 to $17.7m in H1 2021.

 

Finance Expenses

 

Our net finance cost reduced from $1.6m in H1 2020 to $1.1m.

 

Loss Before Tax

 

Loss before tax for the period of $2.6m is after charging $1.2m of non-underlying costs and a foreign exchange loss on borrowings of $3.6m, being a non-cash item.

 

Cash Generation

 

The Group generated a net cash inflow from operating activities of $15.4m in H1 2021 compared to a net outflow of $(2.5)m in H1 2020.

 

Cash Position

 

The Group's cash at 30 June 2021 was $37.7m compared to $28.6m at 30 June 2020.

 

Net Assets

 

The Group's net assets increased from $58m at 30 June 2020 to $147m at 30 June 2021.

 

Net Debt

 

The Group's net debt excluding leasing has decreased from $26.9m as at 31 December 2020 to $16.9m as at 30 June 2021.

 

Earnings Per Share

 

The Group's underlying basic earnings per share of the 6 months to 30 June 2021 was $0.17 compared to $0.01 for the 6 months to 30 June 2020.

 

 

Underlying EBITDA

The below table shows how Underlying EBITDA is calculated:

 

 

 

6 months ended 30 June 2021

 

6 months ended 30 June 2020

 

12 months ended 31 December 2020

 

 

 

 

 

 

$'000

 

$'000

 

$'000

 

 

 

 

Operating profit/(loss)

 

 

3,341

 

(1,728)

 

(2,940)

 

 

 

 

Movement in fair value on derivatives

 

-

 

(727)

 

(740)

 

 

 

 

Operating profit/(loss) after movement in derivative

 

3,341

 

(2,455)

 

(3,680)

 

 

 

 

Add back: Share based payment expense

 

 

680

 

 

766

 

1,706

 

 

 

 

Add back: Restructuring costs

 

-

 

-

 

185

 

 

 

 

Add back: Foreign exchange on funding for  acquisitions

 

 

-

 

 

-

 

1,085

 

 

 

 

Add back: Post acquisition insurance costs

 

-

 

-

 

563

 

 

 

 

 

Underlying EBITDA segmental information

Underlying EBITDA by reportable segment (as defined in note 4) for the six months ended 30 June 2021 is as follows:

 

  Frames and

 

Wholesale

 

Lenses

 

Total before

 

Adjustments

 

  Total

 

  Optics

 

 

 

 

 

adjustments &

 

& elimination

 

 

 

 

 

 

 

 

 

eliminations

 

 

 

 

 

  $'000

 

 $'000

 

$'000

 

$'000

 

$'000

 

 $'000

Revenue

110,449

 

13,643

 

4,278

 

128,370

 

(2,624)

 

  125,746

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit

1,996

 

2,213

 

(793)

 

3,416

 

(75)

 

3,341

Add back:

 

 

 

 

 

 

 

 

 

 

 

Amortisation

2,928

 

524

 

-

 

3,452

 

-

 

3,452

Depreciation

3,182

 

699

 

250

 

4,131

 

-

 

4,131

Share based payments

401

 

279

 

-

 

680

 

-

 

680

PPA adjustment Eschenbach

  inventory

6,104

 

-

 

-

 

6,104

 

-

 

6,104

Underlying EBITDA

14,611

 

3,715

 

(543)

 

17,783

 

(75)

 

17,708

 

 

 

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the period ended 30 June 2021

 

Notes

Unaudited
6 months ended
30 June 2021

 

Unaudited
6 months ended
30 June 2020

 

 

 

  $'000 

 

  $'000 

 

REVENUE

4

125,746

 

16,727

 

Cost of sales

 

(69,248)

 

(9,288)

 

 

 

 

 

 

 

GROSS PROFIT

 

56,498

 

7,439

 

 

 

 

 

 

 

OPERATING PROFIT/(LOSS)

 

3,341

 

(1,728)

 

 

 

 

 

 

 

LOSS BEFORE INCOME TAX

 

(2,630)

 

(8,312)

 

 

 

 

 

 

 

LOSS FOR THE PERIOD

 

(3,163)

 

  (7,489)

 

OTHER COMPREHENSIVE INCOME:

 

 

 

 

 

TOTAL COMPREHENSIVE PROFIT /(LOSS) FOR THE PERIOD

 

633

 

  (8,979)

 

 

Earnings per share

 

 

 

 

 

Basic EPS for the period attributable

  to the equity holders of the parent

5

(0.03)

 

(0.12)

 

 

Diluted EPS for the period attributable

  to the equity holders of the parent

5

(0.03)

 

(0.12)

 

                           

 

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION 

As at 30 June 2021

 

 

 

 

Notes

 

Unaudited

As at
30 June 2021

$'000

 

Unaudited

As at

30 June 2020

$'000

 

Audited

As at
31 December 2020

$'000

 

ASSETS

 

 

 

 

 

 

 

 

 

NON-CURRENT ASSETS

 

 

 

 

 

 

 

 

 

Goodwill

 

 

 

69,961

 

11,982

 

69,087

 

Intangible assets

 

 

 

50,738

 

15,930

 

56,305

 

Property Plant and equipment

 

 

 

42,620

 

11,980

 

42,839

 

Investment in associates

 

 

 

57

 

53

 

57

 

Deferred tax

 

 

 

12,569

 

1,167

 

12,995

 

 

 

 

 

175,945

 

41,112

 

181,283

 

CURRENT ASSETS

 

 

 

 

 

 

 

 

 

Inventories

 

 

 

50,639

 

8,450

 

59,294

 

Trade and other receivables

 

6

 

34,498

 

8,731

 

35,648

 

Tax receivable

 

 

 

246

 

-

 

1,556

 

Cash and cash equivalents

 

 

 

37,718

 

28,589

 

32,672

 

 

 

 

 

123,101

 

45,770

 

129,170

 

TOTAL ASSETS

 

 

 

299,046

 

86,882

 

310,453

 

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

 

 

SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

Called up share capital

 

 

 

1,384

 

968

 

1,384

 

Share premium

 

 

 

121,940

 

35,138

 

121,940

 

Foreign currency translation reserve

 

 

 

3,697

 

(1,385)

 

(99)

 

Share option reserve

 

 

 

1,547

 

564

 

867

 

Merger reserve

 

 

 

7,296

 

7,296

 

7,296

 

Retained earnings

 

 

 

11,266

 

15,853

 

14,429

 

 

TOTAL EQUITY

 

 

 

147,130

 

 

58,434

 

145,817

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

NON-CURRENT LIABILITIES

 

 

 

 

 

 

 

 

Financial liabilities - borrowings

 

 

 

 

 

 

 

 

  Interest bearing loans and borrowings

 

8

 

63,191

 

17,401

 

70,391

 

Deferred tax

 

 

 

21,421

 

2,762

 

24,694

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

84,612

 

20,163

 

95,085

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

7

 

38,542

 

5,611

 

42,895

 

Right of return liability

 

 

 

13,015

 

454

 

12,824

 

Financial liabilities - borrowings

 

 

 

 

 

 

 

 

 

  Interest bearing loans and borrowings

 

8

 

10,191

 

599

 

6,830

 

  Bank overdrafts

 

8

 

-

 

-

 

2,642

 

 Invoice discounting

 

8

 

-

 

47

 

-

 

Tax payable

 

 

 

5,556

 

1,574

 

4,360

 

 

 

 

 

67,304

 

8,285

 

69,551

 

TOTAL LIABILITIES

 

 

 

151,916

 

28,448

 

164,636

 

 

 

 

 

 

 

 

 

 

 

TOTAL EQUITY AND LIABILITIES

 

 

 

299,046

 

86,882

 

310,453

 

                                                           

 

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the period ended 30 June 2021

 

 

 

  Called up share capital

Share premium

Foreign currency translation reserve

Share option reserve

Retained earnings

Merger reserve

Total equity

 

$000

$000

$000

$000

$000

$000

$000

 

 

 

 

 

 

 

 

SIX MONTHS ENDED 30 JUNE 2021

 

 

 

 

 

 

 

Balance at 1 January 2021

1,384

121,940

(99)

867

14,429

7,296

145,817

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

-

(3,163)

-

(3,163)

Other comprehensive income

-

-

3,796

-

-

-

3,796

Total comprehensive loss

-

-

3,796

-

(3,163)

-

633

 

 

 

 

 

 

 

 

Share-based payments

-

-

-

680

-

-

680

Balance at 30 June 2021 (unaudited)

1,384

121,940

3,697

1,547

11,266

7,296

147,130

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIX MONTHS ENDED 30 JUNE 2020

 

 

 

 

 

 

 

Balance at 1 January 2020

62

21,628

1,031

2,840

5,787

-

31,348

 

 

 

 

 

 

 

 

Loss for the period

-

-

-

-

(7,489)

-

(7,489)

Other comprehensive loss

-

-

(1,490)

-

-

-

(1,490)

Total comprehensive loss

-

-

(1,490)

-

-

-

(8,979)

 

 

 

 

 

 

 

 

Issue of share capital

187

32,413

-

-

-

(22)

32,578

Exercise of share options

99

2,725

-

(3,140)

2,973

-

2,657

Share-based payments

-

-

-

830

-

-

830

Share for share exchange and

  creation of merger reserve

620

(21,628)

(926)

34

(46,902)

68,802

-

Capital reduction

-

-

-

-

61,484

(61,484)

-

Balance at 30 June 2020 (unaudited)

968

35,138

(1,385)

564

15,853

7,296

58,434

 

 

 

 

 

 

 

 

 

INTERIM CONSOLIDATED STATEMENT OF CASH FLOW 
For the period ended 30 June 2021

 

 

 

 

 

 

 

 

Unaudited

6 months ended

30 June 2021

 

 

Unaudited

6 months ended

30 June 2020

 

 

 

 

$000

 

$000

 

Cash flows from operating activities

 

 

 

 

 

 

(Loss)/profit before income tax

 

 

(2,630)

 

(8,312)

 

Depreciation charges

 

 

4,131

 

1,155

 

Amortisation charges

 

 

3,451

 

484

 

Share based payments

 

 

680

 

766

 

Movement in fair value of derivatives

 

 

-

 

727

 

Exchange adjustments on borrowings

 

 

3,619

 

1,774

 

Finance costs

 

 

1,123

 

1,570

 

Finance income

 

 

(19)

 

(19)

 

 

 

 

10,355

 

(1,856)

 

Decrease in inventories

 

 

9,406

 

266

 

Decrease in trade and other receivables

 

 

1,600

 

4,143

 

Decrease in trade and other payables

 

 

(4,869)

 

(4,605)

 

Cash generated from operations

 

 

16,492

 

(2,051)

 

Interest paid

 

 

(1,115)

 

(481)

 

Tax paid

 

 

-

 

 

Net cash flow from operating activities

 

 

15,377

 

 

 

 

 

 

 

 

 

Cash flows (used in)/from investing activities

 

 

 

 

 

 

Purchase of intangible fixed assets

 

 

(86)

 

(72)

 

Purchase of property plant and equipment

 

 

(2,697)

 

(265)

 

Interest received

 

 

19

 

19

 

Net cash flows (used in)/from investing

activities

 

 

 

(2,764)

 

 

(318)

 

 

 

 

 

 

 

 

Cash flow from financing activities

 

 

 

 

 

 

Bank loan principal repayments in year

 

 

(3,102)

 

(2,307)

 

Repayment of other loans

 

 

-

 

(2,530)

 

Inflow from Initial Public Offering

 

 

-

 

30,313

 

Principal payments on leases

 

 

(1,920)

 

(590)

 

Net cash flows used in financing

 activities

 

 

 

(5,022)

 

 

24,886

 

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash

 equivalents

 

 

7,591

 

22,035

 

Cash and cash equivalents at

 beginning of the period

 

 

30,030

 

6,502

 

Net foreign currency movements

 

 

97

 

52

 

Cash and cash equivalents

 at end of period

 

 

 

37,718

 

28,589

 

                               

 

 

 

 

 

NOTES TO THE INTERIM CONSOLIDATED STATEMENTS

For the period ended 30 June 2021

 

1.  GENERAL INFORMATION

INSPECS Group plc is a public company limited by shares and is incorporated in England and Wales. The address of the Company's principal place of business is Kelso Place, Upper Bristol Road, Bath BA1 3AU.

The principal activity of the Group in the period was that of design, production, sale, marketing and distribution of high fashion eyewear and OEM products worldwide.

2.  ACCOUNTING POLICIES

Going concern

Based on the Group's forecasts considered in the light of the Covid-19 situation, the Directors have adopted the going concern basis in preparing the interim financial statements.

The assessment has considered the Group's current financial position as follows:

The Group improved its cash position during the period with net cash inflows from operating activities of $15.4m compared to an outflow of ($2.5m) for H1 2020.

The Groups net assets were $147m at the end of the period compared to $58m at 30 June 2020.

The Group has significant headroom with its current and projected covenants with HSBC.

 

30 June 2021

31 December 2020

Actual

Required

Actual

Required

Leverage (excl. leasing)

0.6

Below 2.5

1.6

Below 2.5

Interest cover

21.0

Above 4.0

17.1

Above 4.0

Leverage is calculated on a rolling 12 month historical EBITDA against current net debt excluding leasing.

The assessment has considered the current measures being put in place by the Group to preserve cash and ensure continuity of operations through:

Ensuring continuation of its supply chain buildings on the benefit of having its own manufacturing sites and by securing alternative third-party supply lines.

Maintaining geographical sales diversification, focusing sales to online customers and seeking new revenue streams around the globe.

Ability to service both the major global retail chains and significant distribution to the independent eyewear market following the acquisition of Eschenbach on 16 December 2020.

 

Basis of preparation

The interim consolidated financial statements for the six months ended 30 June 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting and with accounting policies that are consistent with the Group's Annual Report and Financial Statements for the period ended 31 December 2020.

The comparative financial information for the period ended 30 June 2020 in this interim report does not constitute statutory accounts for that period under 434 of the Companies Act 2006 and is unaudited.

Accounting policies are included in detail within the latest Annual Report.

NOTES TO THE INTERIM CONSOLIDATED STATEMENTS (continued)

For the period ended 30 June 2021

 

3.  CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

The preparation of the Group's historical information requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities in the future.

Estimation uncertainty

In addition to the impact of Covid-19 discussed within the going concern section of note 2, the key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period, are described below.

Uncertain tax positions

Tax authorities could challenge and investigate the Group's transfer pricing or tax domicile arrangements. As a growing, international business, there is an inherent risk that local tax authorities around the world could challenge either historical transfer pricing arrangements between other entities within the Group and subsidiaries or branches in those local jurisdictions, or the tax domicile of subsidiaries or branches that operate in those local jurisdictions.

As a result, the Group has identified it is exposed to uncertain tax positions, which it has measured using an expected value methodology. Such methodologies require estimates to be made by management including the relative likelihood of each of the possible outcomes occurring, the periods over which the tax authorities may raise a challenge to the Group's transfer pricing or tax domicile arrangements; and the quantum of interest and penalties payable in addition to the underlying tax liability. As a result, the Group has made a provision of $3,067,000 as at 30 June 2021 ($2,603,000 as at 30 June 2020), in line with the accounting methodology used as at 31 December 2020.

Right of return

Under IFRS15 a sale with right of return is recognised if the customer receives any combination of a full or partial refund of any consideration paid, a credit that can be applied against amounts owed, or another product in exchange. The Group includes within the liability arrangements where the Group has historically accepted a right to return. The Group estimates the impact of potential returns from customers based on historical data on returns, with a liability recognised for the goods expected to be returned. Calculations of this liability require estimation to be made by management as to the expected level of returns. The right of return liability as at 30 June 2021 was $13,015,000 (30 June 2020: $454,000) with Eschenbach accounting for $12,344,000 of this balance as at 30 June 2021.

4.  SEGMENT INFORMATION

The Group operates in three operating segments, which upon application of the aggregation criteria set out in IFRS 8 Operating Segments results in three reporting segments:

• Frames and Optics (previously Branded) product distribution.

• Wholesale - being OEM and manufacturing distribution.

• Lenses - being manufacturing and distribution of lenses.

The acquisition of Norville (20/20) Limited during H2 2020 has led to an additional operating and reporting segment of 'Lenses' in 2020. In addition, the acquisition of Eschenbach Holdings GmbH also in H2 2020 has resulted in a change to the 'Branded' reporting segment, to form the 'Frames and Optics' reporting segment of which Eschenbach is a part during the period to 30 June 2021.

The criteria applied to identify the operating segments are consistent with the way the Group is managed. In particular, the disclosures are consistent with the information regularly reviewed by the CEO and the CFO in their role as Chief Operating Decision Makers, to make decisions about resources to be allocated to the segments and to assess their performance

The reportable segments subject to disclosure are consistent with the organisation model adopted by the Group during the six months ended 30 June 2021 and are as below:

 

  Frames and

 

Wholesale

 

Lenses

 

Total before

 

Adjustments

 

  Total

 

  Optics

 

 

 

 

 

adjustments &

 

& elimination

 

 

 

 

 

 

 

 

 

eliminations

 

 

 

 

 

  $'000

 

 $'000

 

$'000

 

$'000

 

$'000

 

  $'000

Revenue

 

 

 

 

 

 

 

 

 

 

 

  External

109,233

 

12,261

 

4,252

 

125,746

 

-

 

125,746

 

  Internal

1,216

 

1,382

 

26

 

2,624

 

(2,624)

 

-

 

 

110,449

 

13,643

 

4,278

 

128,370

 

(2,624)

 

125,746

 

Cost of sales

(59,588)

 

(9,442)

 

(2,473)

 

(71,503)

 

2,255

 

(69,248)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

50,861

 

4,201

 

1,805

 

56,867

 

(369)

 

56,498

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

(48,865)

 

(1,988)

 

(2,598)

 

(53,451)

 

294

 

(53,157)

 

Operating (loss)/profit

1,996

 

2,213

 

(793)

 

3,416

 

(75)

 

3,341

 

Exchange adjustment

  on borrowings

 

 

 

 

 

 

 

 

 

 

  (3,619)

Non-underlying

  costs - acquisitions

 

 

 

 

 

 

 

 

 

 

(1,248)

Finance costs

 

 

 

 

 

 

 

 

 

 

(1,123)

Finance income

 

 

 

 

 

 

 

 

 

 

19

Taxation

 

 

 

 

 

 

 

 

 

 

(533)

Loss for the period

 

 

 

 

 

 

 

 

 

 

(3,163)

                                   

 

Reported segments relating to the balance sheet as at 30 June 2021 are as follows:

 

  Frames and

 

 Wholesale

 

Lenses

 

Total before

 

Adjustments

 

  Total

 

  Optics

 

 

 

 

 

adjustments &

 

& elimination

 

 

 

 

 

 

 

 

 

 eliminations

 

 

 

 

 

  $'000

 

  $'000

 

 
$'000

 

 
 $'000

 

 
$'000

 


$'000

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

390,712

 

74,917

 

7,285

 

472,914

 

(186,437)

 

286,477

Total liabilities

(302,660)

 

(7,056)

 

(6,837)

 

(316,553)

 

264,996

 

(51,557)

 

88,052

 

67,861

 

448

 

156,361

 

78,559

 

234,920

Deferred tax asset

 

 

 

 

 

 

 

 

 

 

12,569

Deferred tax liability

 

 

 

 

 

 

 

 

 

 

  (21,421)

Current tax liability

 

 

 

 

 

 

 

 

 

 

(5,556)

Borrowings

 

 

 

 

 

 

 

 

 

 

(73,382)

Group net assets

 

 

 

 

 

 

 

 

 

 

147,130

                                 

 

Total assets are the Group's gross assets excluding deferred tax asset. Total liabilities are the Group's gross liabilities excluding loans and borrowings, and deferred tax liability.

The reportable segments subject to disclosure are consistent with the organisation model adopted by the Group during the six months ended 30 June 2020 and are as below:

 

  Branded

 

Wholesale

 

Total before

 

Adjustments

 

  Total

 

 

 

 

 

adjustments &

 

& elimination

 

 

 

 

 

 

 

eliminations

 

 

 

 

 

  $'000

 

  $'000

 

$'000

 

$'000

 

  $'000

Revenue

 

 

 

 

 

 

 

 

 

  External

8,627

 

8,100

 

16,727

 

-

 

16,727

  Internal

1,104

 

894

 

1,998

 

(1,998)

 

-

 

  9,732

 

 8,994

 

 18,726

 

(1,998)

 

  16,727

Cost of sales

(5,886)

 

(5,167)

 

(11,053)

 

  1,765

 

(9,288)

 

 

 

 

 

 

 

 

 

 

Gross profit

3,845

 

 3,827

 

 7,672

 

  (233)

 

7,439

 

 

 

 

 

 

 

 

 

 

Expenses

  (5,205)

 

 (4,153)

 

 (9,358)

 

191

 

(9,167)

Operating (loss)/profit

(1,360)

 

(326)

 

(1,686)

 

  (42)

 

(1,728)

Exchange adjustment

  on borrowings

 

 

 

 

 

 

 

 

 

(1,774)

Movement in derivatives

 

 

 

 

 

 

 

 

(727)

Initial Public Offering costs

 

 

 

 

 

 

 

 

(2,442)

Non-underlying

  costs - restructuring

 

 

 

 

 

 

 

 

(91)

Finance costs

 

 

 

 

 

 

 

 

(1,570)

Finance income

 

 

 

 

 

 

 

 

19

Taxation

 

 

 

 

 

 

 

 

823

Loss for the period

 

 

 

 

 

 

 

 

  (7,489)

 

Reported segments relating to the balance sheet as at 30 June 2020 are as follows:

 

  Frames and

 

 Wholesale

 

Total before

 

Adjustments

 

  Total

 

  Optics

 

 

 

adjustments &

 

& elimination

 

 

 

 

 

 

 

  eliminations

 

 

 

 

 

  $'000

 

 

  $'000

 

  $'000

 

  $'000

 

 

  $'000

Total assets

75,019

 

63,259

 

138,278

 

(52,564)

 

85,714

Total liabilities

(63,712)

 

(4,654)

 

(68,366)

 

62,255

 

(6,111)

 

11,307

 

58,605

 

69,912

 

9,691

 

79,603

Deferred tax asset

 

 

 

 

 

 

 

 

1,167

 

Deferred tax liability

 

 

 

 

 

 

 

 

(2,762)

 

Current tax liability

 

 

 

 

 

 

 

 

(1,574)

 

Borrowings

 

 

 

 

 

 

 

 

(18,000)

 

Group net assets

 

 

 

 

 

 

 

 

58,434

 

 

Total assets are the Group's gross assets excluding deferred tax asset. Total liabilities are the Group's gross liabilities excluding loans and borrowings, and deferred tax liability.

Acquisition costs, finance costs and income, and taxation are not allocated to individual segments as the underlying instruments are managed on a Group basis.

Deferred tax and borrowings are not allocated to individual segments as they are managed on a Group basis.

Adjusted items relate to elimination of all intra-Group items including any profit adjustments on intra-Group sales that are eliminated on consolidation, along with the profit and loss items of the parent company.

Adjusted items in relation to segmental assets and liabilities relate to the elimination of all intra-Group balances and investments in subsidiaries, and assets and liabilities of the parent company.

The revenue of the Group is attributable to the one principal activity of the Group.

 

Geographical analysis

The Group's revenue by destination is split in the following geographic areas:

 

 

 

 

Unaudited

6 months ended

30 June 2021

 

 

Unaudited

6 months ended

30 June 2020

 

 

 

 

 

 

 

 

$'000s

 

$'000s

United Kingdom

 

 

12,339

 

3,253

Europe (excluding UK)

 

 

68,721

 

6,726

North America

 

 

40,968

 

3,617

South America

 

 

169

 

278

Asia

 

 

2,369

 

1,939

Australia

 

 

1,180

 

914

 

 

 

125,746

 

16,727

 

 

 

 

 

 

5.  EARNINGS PER SHARE

Basic Earnings per Share ("EPS") is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.

Diluted EPS is calculated by dividing the profit attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares, to the extent that the inclusion of such shares is not anti-dilutive. During the periods ended 30 June 2021 and 30 June 2020 the Group made a loss; therefore, diluted EPS is not applicable as the impact of potential ordinary shares is anti-dilutive. Basic earnings per share is therefore $(0.03) (30 June 2020: $(0.12)), with diluted earnings per share $(0.03) (30 June 2020: $(0.12)). The following table reflects the income and share data used in the basic and diluted EPS calculations:

 

 

 

30 June

2021

 

30 June

2020

SHARES

 

 

 

 

 

 

 

 

$'000

 

$'000

(Loss)/Profit attributable to the

 

 

 

 

 

equity holders of the parent for basic earnings

 

 

  (3,163)

 

  (7,489)

 

 

 

 

 

 

 

 

 

Number

of shares

 

Number

of shares

Weighted average number of

 

 

 

 

 

shares for basic EPS

 

 

101,290,898

 

61,384,358

Effect of dilution from:

 

 

 

 

 

Share options

 

 

4,211,782

 

4,423,633

Weighted average number of shares

 

 

 

 

 

adjusted for the effect of dilution

 

 

105,502,680

 

65,807,991

 

 

 

 

 

 

 

6.  TRADE AND OTHER RECEIVABLES

 

 

 

 

Unaudited

As at

30 June 2021

 

 

Unaudited

As at

30 June 2020

 

 

As at

31 December

2020

 

 

 

 

  $'000

 

  $'000

 

  $'000

Trade receivables

 

 

27,000

 

6,707

 

25,149

Prepayments

 

 

3,552

 

959

 

6,419

Other receivables

 

 

3,946

 

1,068

 

4,080

 

 

 

 

 

 

 

 

 

 

 

34,498

 

8,731

 

35,648

 

7.  TRADE AND OTHER PAYABLES

 

Unaudited

 

Unaudited

 

As at

  31 December

2020

 

As at

 

As at

 

 

30 June 2021

 

30 June 2020

 

 

$'000

 

 

$'000

 

 

$'000

Trade payables

19,678

 

2,857

 

22,404

Amounts owed to related parties

147

 

201

 

169

Other payables

614

 

277

 

1,435

Social security and other taxes

6,380

 

100

 

5,422

Royalties & provisions

2,453

 

690

 

5,911

Accruals

9,270

 

1,486

 

7,554

 

 

 

 

 

 

 

38,542

 

5,611

 

42,895

 

8.  NET DEBT

 

Unaudited

 

Unaudited

 

As at

  31 December

2020

 

As at

 

As at

 

 

30 June 2021

 

30 June 2020

 

 

$'000

 

 

$'000

 

 

$'000

Cash and cash equivalents

37,718

 

28,589

 

32,672

Interest bearing borrowings excl. leasing

(54,630)

 

(17,182)

 

(56,947)

Bank overdrafts

-

 

-

 

(2,642)

Invoice discounting

-

 

(47)

 

-

Net debt excluding leasing

(16,912)

 

11,360

 

(26,917)

 

 

 

 

 

 

Lease liability

(18,752)

 

(818)

 

(20,274)

Net debt including leasing

(35,664)

 

10,542

 

(47,191)

 

 

 

 

 

 

               

9.  NON-UNDERLYING COSTS

Non-underlying costs in the period relate to the accounting of the acquisition of Eschenbach. Prior period non-underlying costs relate to redundancy costs of Algha Group Limited employees, with the site ceasing trading during the period as part of a planned movement of production to Italy.

 

10.  SHARE-BASED PAYMENTS

Certain employees of the Group are granted options over the shares in INSPECS Group. The options are granted with a fixed exercise price and have vesting dates of between one and three years after date of grant.

The Group recognises a share-based payment expense based on the fair value of the awards granted, and an equivalent credit directly in equity to share option reserve. On exercise of the shares by the employees, the Group is charged the intrinsic value of the shares by INSPECS Group plc and this amount is treated as a reduction of the capital contribution, and it is recognised directly in equity.

Share options outstanding at the end of the year have the following expiry date and exercise prices:

 

Grant date

 

Expected life of

options

Exercise price per option $

Number of share options

 

 

11 October 2019

 

1-3 years

1.27

824,197

 

27 February 2020

 

3-5 years

2.52

1,923,110

 

22 December 2020

 

3-5 years

2.87

1,460,000

 

21 June 2021

 

3-5 years

4.86

90,000

 

The exercise price under each option agreement is denominated in GBP, with the USD balance shown above converted at the rate the option was issued.

 

11.  POST BALANCE SHEET EVENTS

Since the end of the interim period on 30 June 2021 there were no material events that the directors consider material to the users of these interim statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR SSDFLWEFSESU
UK 100

Latest directors dealings